Patents by Inventor Donmienne Doen Mun Leung

Donmienne Doen Mun Leung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN INTERLEUKIN-4 RECEPTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES
    Publication number: 20240100176
    Abstract: The present disclosure provides human interleukin 4 receptor alpha antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of inflammatory diseases, such as type 2 inflammatory diseases.
    Type: Application
    Filed: May 31, 2023
    Publication date: March 28, 2024
    Inventors: Shane Krummen Atwell, Joshua R Clayton, Yiqing Feng, Maya Rachel Karta, Donmienne Doen Mun Leung, Songqing Na, Kristin Paige Newburn, Laura Anne Pelletier, Diana Isabel Ruiz, David John Stokell, Jacqueline M Wurst, Scott Paul Bauer
  • HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES
    Publication number: 20240082414
    Abstract: The present disclosure provides human tumor necrosis factor alpha antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of autoimmune and inflammatory diseases.
    Type: Application
    Filed: May 5, 2023
    Publication date: March 14, 2024
    Inventors: Grace Chao, Joshua R Clayton, Jordan Scott Crampton, Yiqing Feng, Donmienne Doen Mun Leung, Songqing Na, Kristin Paige Newburn, Scott Charles Potter, Bharathi Ramamurthy, David John Stokell, Jacqueline M. Wurst, Jianghuai Xu
  • HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODIES
    Publication number: 20230192837
    Abstract: The present disclosure relates to antibodies that specifically bind soluble and membrane forms of human TNF?, compositions comprising such TNF? antibodies, and methods of using such TNF? antibodies and compositions.
    Type: Application
    Filed: November 10, 2022
    Publication date: June 22, 2023
    Inventors: Grace Chao, Yiqing Feng, Donmienne Doen Mun Leung, Songqing Na, Bharathi Ramamurthy, Jianghuai Xu
  • GLUCOCORTICOID RECEPTOR AGONISTS
    Publication number: 20220306680
    Abstract: The present invention provides a compound of Formula I: wherein R is hydrogen, —P(?O)(OH)2, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, and inflammatory bowel disease.
    Type: Application
    Filed: March 22, 2022
    Publication date: September 29, 2022
    Inventors: Donmienne Doen Mun LEUNG, Jacqueline Mary WURST, James Andrew JAMISON
  • Engineered Antibody Compounds and Conjuates Thereof
    Publication number: 20200155702
    Abstract: Engineered antibody compounds and conjugates thereof, are provided, said antibody compounds and conjugates thereof are useful as agents for cancer immunotherapy.
    Type: Application
    Filed: June 14, 2018
    Publication date: May 21, 2020
    Inventors: Michael James Bacica, Yiqing Feng, Donmienne Doen Mun Leung, Matthew D. Linnik, Adam Robert Mezo, James Thomas Parker, Purva Vivek Trivedi, Francisco Alcides Valenzuela, Jianghuai Xu
  • VEGFA/Ang2 Compounds
    Patent number: 9932397
    Abstract: The present invention relates to compounds that bind to human vascular endothelial growth factor A (VEGFA) and human angiopoietin-2 (Ang2), and may be useful for treating angiogenic eye diseases, such as diabetic and other proliferative retinopathies, and for cancer, especially solid tumors driven by VEGFA and Ang2, including gastric, lung, hepatocellular carcinoma, ovarian, colorectal, and breast cancers.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: April 3, 2018
    Assignee: Eli Lilly and Company
    Inventors: Donmienne Doen Mun Leung, Ying Tang, Peter Edward Vaillancourt, Jianghuai Xu
  • Ang2 antibodies
    Patent number: 9695241
    Abstract: The present invention relates to antibodies that bind human angiopoietin-2 (Ang2), and may be useful for treating cancer alone and in combination with VEGF pathway inhibitors, especially cancer driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, and breast cancers.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: July 4, 2017
    Assignee: Eli Lilly and Company
    Inventors: Donmienne Doen Mun Leung, Jianghuai Xu
  • VEGFR2/Ang2 Compounds
    Publication number: 20170121411
    Abstract: The present invention relates to compounds that bind to human vascular endothelial growth factor receptor-2 (VEGFR2) and human angiopoietin-2 (Ang2), and may be useful for treating cancer, especially solid tumors driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, non-small cell lung, biliary tract, and breast cancers.
    Type: Application
    Filed: January 17, 2017
    Publication date: May 4, 2017
    Inventors: Donmienne Doen Mun LEUNG, Ling LIU, Jirong LU, Ying TANG, Jianghuai XU
  • VEGFR2/Ang2 compounds
    Patent number: 9580499
    Abstract: The present invention relates to compounds that bind to human vascular endothelial growth factor receptor-2 (VEGFR2) and human angiopoietin-2 (Ang2), and may be useful for treating cancer, especially solid tumors driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, non-small cell lung, biliary tract, and breast cancers.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: February 28, 2017
    Assignee: Eli Lilly and Company
    Inventors: Donmienne Doen Mun Leung, Ling Liu, Jirong Lu, Ying Tang, Jianghuai Xu
  • Anti-TNF-anti-IL-17 bispecific antibodies
    Patent number: 9416182
    Abstract: Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNF?) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS).
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: August 16, 2016
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Andrew Lawrence Glasebrook, Jirong Lu, Ying Tang, Derrick Ryan Witcher, Donmienne Doen Mun Leung, Pia Pauliina Yachi, Andrew Charles Vendel
  • VEGFA/Ang2 Compounds
    Publication number: 20160215045
    Abstract: The present invention relates to compounds that bind to human vascular endothelial growth factor A (VEGFA) and human angiopoietin-2 (Ang2), and may be useful for treating angiogenic eye diseases, such as diabetic and other proliferative retinopathies, and for cancer, especially solid tumors driven by VEGFA and Ang2, including gastric, lung, hepatocellular carcinoma, ovarian, colorectal, and breast cancers.
    Type: Application
    Filed: January 25, 2016
    Publication date: July 28, 2016
    Inventors: Donmienne Doen Mun Leung, Ying Tang, Peter Edward Vaillancourt, Jianghuai Xu
  • Variants of human GDNF
    Patent number: 9243046
    Abstract: The present invention relates to novel variants of human glial cell-derived neurotrophic factor (GDNF) and methods for their use.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: January 26, 2016
    Assignee: Eli Lilly and Company
    Inventors: Donmienne Doen Mun Leung, Jirong Lu, Kalpana Mahesh Merchant, Mahmoud Ghanem, Linda Maureen O'Bryan, Rosamund Carol Smith
  • VEGFR2/Ang2 Compounds
    Publication number: 20150329626
    Abstract: The present invention relates to compounds that bind to human vascular endothelial growth factor receptor-2 (VEGFR2) and human angiopoietin-2 (Ang2), and may be useful for treating cancer, especially solid tumors driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, non-small cell lung, biliary tract, and breast cancers.
    Type: Application
    Filed: May 12, 2015
    Publication date: November 19, 2015
    Inventors: Donmienne Doen Mun Leung, Ling Liu, Jirong Lu, Ying Tang, Jianghuai Xu
  • Ang2 Antibodies
    Publication number: 20150329627
    Abstract: The present invention relates to antibodies that bind human angiopoietin-2 (Ang2), and may be useful for treating cancer alone and in combination with VEGF pathway inhibitors, especially cancer driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, and breast cancers.
    Type: Application
    Filed: May 12, 2015
    Publication date: November 19, 2015
    Inventors: Donmienne Doen Mun Leung, Jianghuai Xu
  • ANTI-TNF-ANTI-IL-17 BISPECIFIC ANTIBODIES
    Publication number: 20140255406
    Abstract: Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNF?) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS).
    Type: Application
    Filed: March 4, 2014
    Publication date: September 11, 2014
    Applicant: Eli Lilly and Company
    Inventors: Barrett Allan, Andrew Lawrence Glasebrook, Jirong Lu, Ying Tang, Derrick Ryan Witcher, Donmienne Doen Mun Leung, Pia Pauliina Yachi, Andrew Charles Vendel
  • Anti-hepcidin antibodies and uses thereof
    Patent number: 8765129
    Abstract: Monoclonal antibodies are provided that selectively bind human hepcidin-25 and are characterized as having high affinity for human hepcidin-25 and strong human mature hepcidin neutralizing properties. The antibodies of the invention are useful therapeutically for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment and diagnosis of mature hepcidin-promoted disorders such as anemia, in a human subject.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: July 1, 2014
    Assignee: Eli Lilly and Company
    Inventors: Donmienne Doen Mun Leung, Peng Luan, Barbara Anne Swanson, Ying Tang, Derrick Ryan Witcher
  • Anti-ferroportin 1 monoclonal antibodies and uses thereof
    Patent number: 8679497
    Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the level of serum iron, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a subject in vivo.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: March 25, 2014
    Assignee: Eli Lilly and Company
    Inventors: Donmienne Doen Mun Leung, Peng Luan, Joseph Vincent Manetta, Ying Tang, Derrick Ryan Witcher
  • Anti-hepcidin-25 selective antibodies and uses thereof
    Patent number: 8609817
    Abstract: Monoclonal antibodies are provided that bind to the N-terminus of human hepcidin-25 and are characterized as having high affinity and selectivity for the polypeptide. The antibodies of the invention are useful for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment of various disorders, such as anemia, in a human subject. The antibodies of the invention are also useful as analytical tools, such as in sandwich ELISA.
    Type: Grant
    Filed: July 29, 2009
    Date of Patent: December 17, 2013
    Assignee: Eli Lilly and Company
    Inventors: Donmienne Doen Mun Leung, Peng Luan, Ying Tang, Derrick Ryan Witcher, Pia Pauliina Yachi
  • VARIANTS OF HUMAN GDNF
    Publication number: 20130324474
    Abstract: The present invention relates to novel variants of human glial cell-derived neurotrophic factor (GDNF) and methods for their use.
    Type: Application
    Filed: April 3, 2012
    Publication date: December 5, 2013
    Applicant: Eli Lilly and Company
    Inventors: Donmienne Doen Mun Leung, Jirong Lu, Kalpana Mahesh Merchant, Mahmoud Ghanem, Linda Maureen O'Bryan, Rosamund Carol Smith
  • ANTI-FERROPORTIN 1 MONOCLONAL ANTIBODIES AND USES THEREOF
    Publication number: 20130122013
    Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the level of serum iron, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a subject in vivo.
    Type: Application
    Filed: May 7, 2012
    Publication date: May 16, 2013
    Applicant: ELI LILLY AND COMPANY
    Inventors: Donmienne Doen Mun LEUNG, Peng LUAN, Joseph Vincent MANETTA, Ying TANG, Derrick Ryan WITCHER